Background Glucagon-like peptide1 receptor (GLP-1R) agonists have been found to reduce
alcohol drinking in rodents and overweight patients with alcohol use disorder (AUD) …

Alcohol use disorder (AUD) remains a significant public health concern, affecting around 5%
of adults worldwide. Novel pathways of damage have been described during the last years …

Alcohol-associated liver disease due to harmful alcohol use and NAFLD associated with
metabolic syndrome are the 2 most common liver diseases worldwide. Control of respective …

The mechanisms contributing to alcohol use disorder (AUD) are complex and the orexigenic
peptide ghrelin, which enhances alcohol reward, is implied as a crucial modulator. The …

Preclinical studies have identified glucagon-like peptide-1 receptor (GLP-1R) agonists, and
the antismoking agents varenicline and bupropion as tentative agents for treatment of …

Fatty liver is the earliest response of the liver to excessive alcohol consumption. Previously
we identified that chronic alcohol administration increases levels of stomach-derived …

The human reward network consists of interconnected brain regions that process stimuli
associated with satisfaction and modulate pleasure-seeking behaviors. Impairments in …

Introduction: Glucagon-like peptide 1 receptor (GLP-1R) agonists are widely used in therapy
for type 2 diabetes mellitus (DM2) and obesity. There are also increasing amounts of data …

The underlying neurobiology of alcohol use disorder (AUD) is complex and needs further
unraveling, with one of the key mechanisms being the gut-brain peptide ghrelin and its …

Updates for treatments for youth with type 2 diabetes mellitus and obesity. - Abstract - Europe
PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers …